About
About Kopran Limited
Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, penicillin, quinolone, anti-protozoal, sulphonamides, respiratory, tetracycline, cardiovascular, anti-diabetic, urology, pain management and anti-inflammatory, gastrointestinal, erectile dysfunction, anthemintic, anti-allergic, central nervous system, anti-malarial, anti-thyroid, and carbapenems. In addition, the company offers drugs for anti-hypertensive, neuromodulator, anti-acne, anti-infective, antibiotic, anti-thrombotic, anti-diabetic, anti-asthamatic, antihyperlipidemic, anti-convulsants, anti-anxiety, pulmonary arterial hypertension, chronic heart failure, neuropathic pain, and erosive esophagitis. Kopran Limited was incorporated in 1958 and is based in Mumbai, India.
Research context
Kopran Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 6 months ago
Kopran Limited is currently in a long term uptrend where the price is trading 65.4% above its 200 day moving average.
From a valuation standpoint, the stock is 77.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.1.
Kopran Limited's total revenue rose by 11.8% to $1B since the same quarter in the previous year.
Its net income has increased by 148.8% to $157M since the same quarter in the previous year.
Finally, its free cash flow grew by 104.9% to $347M since the same quarter in the previous year.
Based on the above factors, Kopran Limited gets an overall score of 5/5.